SynAct Pharma AB (“SynAct”) hereby publishes an additional prospectus due to the press release that was published by the company on 30 May 2016, after the company’s prospectus has been approved by Finansinspektionen in preparation for the issue of units with subscription period on May 24 – June 8, 2016.
The press release concerned the election of the independent member Lars Adlersson to the Board of Directors of Synact. The additional prospectus is available at the company’s ( www.synactpharma.se ) , Sedermera Fondkommission’s ( www.sedermera.se ) and Aktietorget’s ( www.aktietorget.se ) and websites respectively.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Henrik Stage
CFO, SynAct Pharma AB
Telephone: +45 40 26 09 00
E-mail: [email protected]
SynAct Pharma AB, Company registration number 559058-4826, is a biotech company that conducts research and development in inflammatory diseases via the wholly owned Danish subsidiary, SynAct Pharma ApS. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma’s main focus is on the development of the candidate drug AP1189, which strengthens the body’s own cells and fights flares in inflammation by accelerating recovery and thereby reducing the risk of chronic inflammation deterioration.